(Q35641260)

9 August 2017

In vitro antimicrobial susceptibility of a Mycobacterium sp. isolated from patients with Crohn's disease (English)

1 reference

9 August 2017

0 references

Chiodini RJ

1

1 reference

9 August 2017

Van Kruiningen HJ

2

1 reference

9 August 2017

Thayer WR

3

1 reference

9 August 2017

Coutu JA

4

1 reference

9 August 2017

Merkal RS

5

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 1984

1 reference

Antimicrobial Agents and Chemotherapy

9 August 2017

1 reference

9 August 2017

26

1 reference

9 August 2017

930-932

1 reference

9 August 2017

6

1 reference

In vitro susceptibility of Mycobacterium fortuitum to cefoxitin

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180053

Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180053

Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180053

In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180053

Mechanism of Antibiotic Resistance inMycobacterium intracellulare

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180053

Disk diffusion testing with polymyxin and amikacin for differentiation of Mycobacterium fortuitum and Mycobacterium chelonei.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180053

The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180053

Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180053

Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180053

Clinical Effect of Metronidazole and Sulfasalazine on Crohn's Disease in Relation to Changes in the Fecal Flora

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/6524906

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Treatment of Crohn's disease with peroral 5-aminosalicylic acid

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/6524906

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Possible role of mycobacteria in inflammatory bowel disease. II. Mycobacterial antibodies in Crohn's disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/6524906

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.26.6.930

1 reference

9 August 2017

1 reference

9 August 2017

1 reference